论文部分内容阅读
目的探讨血管性血友病因子抗原(v WF:Ag)、D-二聚体对多发性骨髓瘤(MM)诊断治疗及预后的临床意义。方法收治的68例多发性骨髓瘤患者为MM组,另同期体检健康者199例为对照组。两组v WF:Ag、D-二聚体的检测采用法国思塔高(STAGO)公司的STAR Evolution全自动血凝分析仪,试剂为法国思塔高公司的血凝配套试剂,严格按说明书操作。结果采用SPSS 18统计学软件处理,MM组和对照组间的v WF:Ag、D-二聚体比较采用F检验和t检验,MM治疗前和缓解后比较采用t检验。结果 v WF:Ag、D-二聚体水平在多发性骨髓瘤组明显高于正常健康组,两组间水平差异具有统计学意义(P<0.05),另外,MM治疗缓解后组比MM治疗前组的血浆v WF:Ag、D-二聚体水平有明显降低,两组间差异具有统计学意义(P<0.05)。结论动态监测血浆v WF:Ag和D-二聚体水平对多发性骨髓瘤的诊疗及预后有重要的临床意义。
Objective To investigate the clinical significance of vWF: Ag and D-dimer in the diagnosis, treatment and prognosis of multiple myeloma (MM). Methods 68 cases of multiple myeloma patients were treated MM group, and the same period the physical examination of 199 cases as control group. The two groups of v WF: Ag, D-dimer were detected by STAGO STAR Evolution automatic hemagglutination analyzer. The reagents were the hemagglutination reagents of STAPCO, and were operated strictly according to the instructions . The results were analyzed by SPSS 18 statistical software. The comparison of vWF: Ag and D-dimer between MM group and control group was made by F test and t test. Before and after MM treatment, t-test was used. Results The levels of vWF: Ag and D-dimer in multiple myeloma group were significantly higher than those in normal healthy group (P <0.05). In addition, the levels of vWF: Ag and D-dimer were significantly higher in MM group than in MM group Plasma vWF: Ag, D-dimer levels in the former group were significantly decreased, with significant differences between the two groups (P <0.05). Conclusions The dynamic monitoring of vWF: Ag and D-dimer levels has important clinical significance in the diagnosis and prognosis of multiple myeloma.